Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Next Previous
X
Search
Trial Profile

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adagrasib (Primary) ; Cetuximab (Primary) ; Aflibercept; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Ramucirumab
  • Indications Carcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KRYSTAL-10; KRYSTAL10
  • Sponsors Mirati Therapeutics

    • Most Recent Events

    • 09 Jan 2025 Planned End Date changed from 28 Feb 2026 to 30 Jan 2026.
    • 09 Jan 2025 Planned primary completion date changed from 28 Feb 2025 to 30 Jan 2026.
    • 12 Mar 2024 Planned End Date changed from 30 Dec 2024 to 28 Feb 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top